Skip to content

Study · Not a test of the peptide alone · 2024

6 results

Glucose-Driven Droplet Formation in Complexes of a Supramolecular Peptide and Therapeutic Protein.

Yu S, Chen W, Liu G, Flores B, DeWolf EL, Fan B, Xiang Y, Webber MJ

Journal of the American Chemical Society11 Mar 2024Cited by 30 (Europe PMC)

PMID38465595 (opens in a new tab)DOI10.1021/jacs.3c13139 (opens in a new tab)PepBankPUB-38465595
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Dasiglucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dasiglucagon.

  1. 01AnimalNot a test of Dasiglucagon aloneAnimal study (in vivo)Efficacy outcome

    In mice with insulin-overdose hypoglycemia, dasiglucagon delivery through droplets mitigated the most severe effects of hypoglycemia.

    In plain wordsIn mice with insulin-overdose hypoglycemia, dasiglucagon delivery through droplets reduced the most severe effects of low blood sugar.

    Peptide
    Dasiglucagon
    Outcome
    DecreaseHypoglycemic rescue
    Study

    mousen: not reported in source

    Insulin overdose hypoglycemia
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    These droplets also offer function in mitigating the most severe effects of hypoglycemia arising from an insulin overdose through delivery of dasiglucagon in a mouse model of hypoglycemic rescue.

    In this study, Dasiglucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dasiglucagon.

  2. 02LabNot a test of Dasiglucagon aloneIn vitro (cell-free)Activity measurement

    In lab tests, dasiglucagon release from glucose-responsive droplets accelerated in the absence of glucose.

    In plain wordsIn lab tests, dasiglucagon release from droplets accelerated without glucose compared with glucose-containing conditions.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseGlucose-responsive release
    Study

    n: not reported in source

    Glucose-responsive stabilized droplets
    Comparator
    Presence of glucose
    Outcome group
    Drug Release · Pharmacology

    Source sentences

    Summary
    This glucose-dependent formation translates into an accelerated release of dasiglucagon in the absence of glucose;
    2 context sentences
    Summary · context
    Here, a net-cationic supramolecular peptide amphiphile building block with a glucose-binding motif is shown that forms LLPS structures when combined with a net-negatively charged therapeutic protein, dasiglucagon, in the presence of glucose.
    Summary · context
    When the stabilized droplets formed in glucose are transferred to a bulk phase containing different glucose concentrations, their stability and lifetime decrease according to bulk glucose concentration.

    In this study, Dasiglucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dasiglucagon.

  3. 03LabNot a test of Dasiglucagon aloneIn vitro (cell-free)Activity measurement

    In lab tests, a glucose-binding peptide amphiphile formed liquid-liquid phase separation structures with dasiglucagon in the presence of glucose.

    In plain wordsIn lab tests, a glucose-binding peptide amphiphile formed droplets with dasiglucagon in the presence of glucose.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableGlucose-dependent droplet formation
    Study

    n: not reported in source

    Peptide amphiphile-dasiglucagon complexes
    Outcome group
    Drug Release · Pharmacology

    Source sentences

    Summary
    Here, a net-cationic supramolecular peptide amphiphile building block with a glucose-binding motif is shown that forms LLPS structures when combined with a net-negatively charged therapeutic protein, dasiglucagon, in the presence of glucose.

    In this study, Dasiglucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dasiglucagon.

  4. 04LabNot a test of Dasiglucagon aloneIn vitro (cell-free)Activity measurement

    In lab tests, droplets formed with dasiglucagon were dynamic and coalesced quickly.

    In plain wordsIn lab tests, droplets formed with dasiglucagon were dynamic and merged quickly.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableDroplet coalescence
    Study

    n: not reported in source

    Peptide amphiphile-dasiglucagon complexes
    Outcome group
    Drug Release · Pharmacology

    Source sentences

    Summary
    The droplets that arise are dynamic and coalesce quickly.
    1 context sentence
    Summary · context
    Here, a net-cationic supramolecular peptide amphiphile building block with a glucose-binding motif is shown that forms LLPS structures when combined with a net-negatively charged therapeutic protein, dasiglucagon, in the presence of glucose.

    In this study, Dasiglucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dasiglucagon.

  5. 05LabNot a test of Dasiglucagon aloneIn vitro (cell-free)Activity measurement

    In lab tests, addition of a 4-arm star PEG stabilized the interface of droplets formed with dasiglucagon.

    In plain wordsIn lab tests, addition of a 4-arm star PEG stabilized the surface of droplets formed with dasiglucagon.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableDroplet interface stabilization
    Study

    n: not reported in source

    Peptide amphiphile-dasiglucagon complexes
    Outcome group
    Drug Release · Pharmacology

    Source sentences

    Summary
    However, the interface can be stabilized by addition of a 4-arm star PEG.
    1 context sentence
    Summary · context
    Here, a net-cationic supramolecular peptide amphiphile building block with a glucose-binding motif is shown that forms LLPS structures when combined with a net-negatively charged therapeutic protein, dasiglucagon, in the presence of glucose.

    In this study, Dasiglucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dasiglucagon.

  6. 06LabNot a test of Dasiglucagon aloneIn vitro (cell-free)Activity measurement

    In lab tests, stabilized dasiglucagon-containing droplets transferred to different glucose concentrations showed decreases in stability and lifetime according to bulk glucose concentration.

    In plain wordsIn lab tests, stabilized dasiglucagon-containing droplets showed decreases in stability and lifetime according to the surrounding glucose concentration.

    Peptide
    Dasiglucagon
    Outcome
    DecreaseGlucose-dependent droplet stability and lifetime
    Study

    n: not reported in source

    Glucose-responsive stabilized droplets
    Outcome group
    Drug Release · Pharmacology

    Source sentences

    Summary
    When the stabilized droplets formed in glucose are transferred to a bulk phase containing different glucose concentrations, their stability and lifetime decrease according to bulk glucose concentration.
    1 context sentence
    Summary · context
    Here, a net-cationic supramolecular peptide amphiphile building block with a glucose-binding motif is shown that forms LLPS structures when combined with a net-negatively charged therapeutic protein, dasiglucagon, in the presence of glucose.

    In this study, Dasiglucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dasiglucagon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.